MedCity News
DECEMBER 25, 2023
Current billing practices do not adequately meet the needs of consumers, providers or payers. While there is no magic wand, reinventing billing processes in the US will require measures that strengthen consumer protection, and continued policy change towards fairer drug pricing and increased price transparency of provider service costs.
Pharmaceutical Technology
DECEMBER 25, 2023
Opaganib is under clinical development by RedHill Biopharma and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 25, 2023
Last month at a conference, AdventHealth CEO Terry Shaw shared some employee retention strategies used at his health system. He stressed the importance of gathering employee feedback and using it to give them the changes they need. This month, MedCity News followed up with AdventHealth to get a better picture of what these strategies look like in practice.
Pharmaceutical Technology
DECEMBER 25, 2023
Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Oligodendroglioma.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
DECEMBER 25, 2023
Executives at LRVHealth expect to see a continued focus on generative AI, increased enrollment in Medicare Advantage and more in 2024.
Pharmaceutical Technology
DECEMBER 25, 2023
Efineptakin alfa is under clinical development by NeoImmuneTech and currently in Phase II for Solid Tumor.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 25, 2023
Disitamab vedotin is under clinical development by RemeGen and currently in Phase I for Cervical Cancer.
Pharmaceutical Commerce
DECEMBER 25, 2023
This year’s PC Podcast episodes ranged in topic, from DSCSA compliance to pharmacovigilance.
Pharmaceutical Technology
DECEMBER 25, 2023
HCW-9218 is under clinical development by HCW Biologics and currently in Phase I for Ovarian Cancer.
PharmExec
DECEMBER 25, 2023
These stories graced the cover of Pharmaceutical Executive this year
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
DECEMBER 25, 2023
Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer.
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 25, 2023
ZB-131 is under clinical development by ZielBio and currently in Phase II for Gallbladder Cancer.
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read pharmacy technician-related articles on Pharmacy Times in 2023.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
DECEMBER 25, 2023
ION-537 is under clinical development by Ionis Pharmaceuticals and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Pharmacy Times
DECEMBER 25, 2023
From newsworthy moments to groundbreaking research, these were the most-read biosimilar-related articles on Pharmacy Times in 2023.
Pharmaceutical Technology
DECEMBER 25, 2023
Cusatuzumab is under clinical development by OncoVerity and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
Pharmaceutical Technology
DECEMBER 25, 2023
Magrolimab is under clinical development by Gilead Sciences and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Central Nervous System (CNS) Tumor.
Pharmaceutical Technology
DECEMBER 25, 2023
Y-101D is under clinical development by Wuhan YZY Biopharma and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).
Pharmaceutical Technology
DECEMBER 25, 2023
Dabrafenib mesylate is under clinical development by Novartis and currently in Phase II for Gastrointestinal Stromal Tumor (GIST).
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Metastatic Colorectal Cancer.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
DECEMBER 25, 2023
Zanidatamab is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Atopic Keratoconjunctivitis.
Pharmaceutical Technology
DECEMBER 25, 2023
BDTX-4933 is under clinical development by Black Diamond Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.
Pharmaceutical Technology
DECEMBER 25, 2023
Capivasertib is under clinical development by AstraZeneca and currently in Phase III for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology
DECEMBER 25, 2023
Taladegib is under clinical development by Endeavor BioMedicines and currently in Phase II for Idiopathic Pulmonary Fibrosis.
Pharmaceutical Technology
DECEMBER 25, 2023
ADCT-901 is under clinical development by ADC Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC).
Pharmaceutical Technology
DECEMBER 25, 2023
NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase III for Diffuse Large B-Cell Lymphoma.
Pharmaceutical Technology
DECEMBER 25, 2023
ABSK-021 is under clinical development by Abbisko Therapeutics and currently in Phase I for Tenosynovial Giant Cell Tumor.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
114 
Let's personalize your content